Jankowski R P, Vahrson H
Med Klin. 1977 Dec 9;72(49):2122-6.
19 patients with advanced ovarian cancer (FIGO-stages IIb-IV) were treated by ultra-high doses of VM26 partly according to positive oncobiograms during Multiple-drug-stoss-therapy. The toxic reactions and the cytostatic effect were investigated. The range of 57,9% remissions and the moderate toxicity suggest a specific application of VM26 in advanced ovarian cancer.
19例晚期卵巢癌(国际妇产科联盟分期IIb-IV期)患者在多药冲击疗法期间,部分根据阳性肿瘤生物学图谱接受了超高剂量的威猛(VM26)治疗。对毒性反应和细胞抑制作用进行了研究。57.9%的缓解率范围和中度毒性表明威猛(VM26)在晚期卵巢癌中有特定的应用价值。